Risk factors for development of carbapenem resistance among gram-negative rods

Open Forum Infectious Diseases

Volumn 6, Issue 3, 2019, Pages

  Richter, Stefan E ^a,b   Miller, Loren ^b   Needleman, Jack ^b   Uslan, Daniel Z ^b   Bell, Douglas ^b   Watson, Karol ^a,b   Humphries, Romney ^b,c   McKinnell, James A ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Accelerate Diagnostics Inc   (United States)

Author keywords

antimicrobial resistance; antimicrobial stewardship; carbapenems; Gram negative rods; predictive scoring

Indexed keywords

CARBAPENEM; DAPTOMYCIN; DORIPENEM; ERTAPENEM; IMIPENEM; LINEZOLID; MEROPENEM; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ANTIPSEUDOMONAL CARBAPENEM RESISTANT GRAM NEGATIVE ROD; ANTIPSEUDOMONAL CARBAPENEM SUSCEPTIBLE GRAM NEGATIVE ROD; ARTICLE; ARTIFICIAL VENTILATION; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIUM CULTURE; BACTERIUM ISOLATION; CARBAPENEM RESISTANCE; ERTAPENEM RESISTANT GRAM NEGATIVE ROD; ERTAPENEM SUSCEPTIBLE GRAM NEGATIVE ROD; GRAM NEGATIVE BACTERIUM; HEALTH CARE FACILITY; HOSPITAL COST; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LENGTH OF STAY; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM;

EID: 85066410485     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofz027     Document Type: Article

References (31)

1. CDC. Antibiotic resistance threats in the United States, 2013. 2013. https://www. cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed 10 November 2016.
2. O'Neill J. AMR review paper - tackling a crisis for the health and wealth of nations. 2014. https://amr-review.org/sites/default/files/AMR Review Paper - Tackling a crisis for the health and wealth of nations_1.pdf. Accessed 10 November 2016.
3. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-74.
4. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-96.
5. MacKenzie FM, Bruce J, Struelens MJ, et al; ARPAC Steering Group. Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals. Clin Microbiol Infect 2007; 13:269-76.
6. Neuhauser MM, Weinstein RA, Rydman R, et al. Antibiotic resistance among gram-negative bacilli in US intensive care units: Implications for fluoroquinolone use. JAMA 2003; 289:885-8.
7. Polk RE, Johnson CK, McClish D, et al. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004; 39:497-503.
8. Torres-Gonzalez P, Cervera-Hernandez ME, Niembro-Ortega MD, et al. Factors associated to prevalence and incidence of carbapenem-resistant Enterobacteriaceae fecal carriage: A cohort study in a Mexican tertiary care hospital. PLoS One 2015; 10:e0139883.
9. Fortin E, Platt RW, Fontela PS, et al. Predicting antimicrobial resistance prevalence and incidence from indicators of antimicrobial use: what is the most accurate indicator for surveillance in intensive care units?. PLoS One 2015; 10:e0145088.
10. Akgul F, Bozkurt I, Sunbul M, et al. Risk factors and mortality in the carbapenem-resistant Klebsiella pneumoniae infection: Case control study. Pathog Glob Health 2016; 110:321-5.
11. Bartsch SM, McKinnell JA, Mueller LE, et al. Potential economic burden of carbapenem-resistant Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017; 23:48.e9-48.e16.
12. de Maio Carrilho CM, de Oliveira LM, Gaudereto J, et al. A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome. BMC Infect Dis 2016; 16:629-637.
13. Zilberberg MD, Nathanson BH, Sulham K, et al. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis. BMC Infect Dis 2017; 17:279-291.
14. Mariappan S, Sekar U, Kamalanathan A. Carbapenemase-producing Enterobacteriaceae: Risk factors for infection and impact of resistance on outcomes. Int J Appl Basic Med Res 2017; 7:32-9.
15. Leibman V, Martin ET, Tal-Jasper R, et al. Simple bedside score to optimize the time and the decision to initiate appropriate therapy for carbapenem-resistant Enterobacteriaceae. Ann Clin Microbiol Antimicrob 2015; 14:31-35.
16. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med 2008; 168:2205-10.
17. Lodise TP Jr, Miller C, Patel N, et al. Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with carbapenem-resistant isolates. Infect Control Hosp Epidemiol 2007; 28:959-65.
18. Yang D, Xie Z, Xin X, et al. A model for predicting nosocomial carbapenem-resistant Klebsiella pneumoniae infection. Biomed Rep 2016; 5:501-5.
19. Meng X, Liu S, Duan J, et al. Risk factors and medical costs for healthcare-associated carbapenem-resistant Escherichia coli infection among hospitalized patients in a Chinese teaching hospital. BMC Infect Dis 2017; 17:82-90.
20. Miller BM, Johnson SW. Demographic and infection characteristics of patients with carbapenem-resistant Enterobacteriaceae in a community hospital: Development of a bedside clinical score for risk assessment. Am J Infect Control 2016; 44:134-7.
21. Viale P, Giannella M, Lewis R, et al. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther 2013; 11:1053-63.
22. Tacconelli E, Cataldo MA, De Pascale G, et al. Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant Acinetobacter baumannii calcoaceticus complex. J Antimicrob Chemother 2008; 62:1130-7.
23. van Walraven C, Austin PC, Jennings A, et al. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care 2009; 47:626-33.
24. Lee SS, Kim Y, Chung DR. Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis. J Infect 2011; 62:159-64.
25. Raman G, Avendano E, Berger S, Menon V. Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: Systematic review and meta-analysis. BMC Infect Dis 2015; 15:395-405.
26. Shorr AF, Micek ST, Welch EC, et al. Inappropriate antibiotic therapy in Gramnegative sepsis increases hospital length of stay. Crit Care Med 2011; 39:46-51.
27. Thom KA, Schweizer ML, Osih RB, et al. Impact of empiric antimicrobial therapy on outcomes in patients with Escherichia coli and Klebsiella pneumoniae bacteremia: A cohort study. BMC Infect Dis 2008; 8:116-124.
28. StataCorp. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP; 2015.
29. Falcone M, Russo A, Iacovelli A, et al. Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Microbiol Infect 2016; 22:444-50.
30. Richter SE, Miller L, Uslan DZ, et al. Risk factors for colistin resistance among gram-negative rods and Klebsiella pneumoniae isolates. J Clin Microbiol. In press.
31. Mann CJ. Observational research methods. Research design II: Cohort, cross sectional, and case-control studies. Emerg Med J 2003; 20:54-60.